|
- Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer
Tarlatamab, a bispecific T-cell engager immunotherapy targeting delta-like ligand 3 and CD3, showed promising antitumor activity in a phase 1 trial in patients with previously treated small-cell
- label - Food and Drug Administration
Tarlatamab-dlle is a bispecific DLL3-directed CD3 T-cell engager that binds to DLL3 expressed on the surface of cells, including tumor cells, and CD3 expressed on the surface of T cells
- Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer
- Tarlatamab - Wikipedia
Tarlatamab, sold under the brand name Imdelltra, is an anti-cancer medication used for the treatment of extensive-stage small cell lung cancer [5] It is a bispecific T-cell engager that binds delta-like ligand 3 and CD3
- Real-world efficacy and safety of tarlatamab in patients with relapsed . . .
Background: Tarlatamab, a bispecific T cell engager targeting Delta-Like ligand 3, received FDA approval in May 2024 for patients with relapsed extensive-stage small cell lung cancer (SCLC)
- Tarlatamab Uses, Side Effects Warnings - Drugs. com
Tarlatamab is used to treat non-small cell lung cancer in adults who are no longer responding to platinum-based chemotherapy Tarlatamab is used when the cancer has progressed or has spread to other parts of the body (metastatic)
- Tarlatamab-dlle - NCI - National Cancer Institute
Tarlatamab-dlle (Imdelltra) works by bringing healthy T cells (immune cells that help kill cancer cells) and lung cancer cells close together so the T cells can more effectively kill the lung cancer cells
- Tarlatamab-dlle (intravenous route) - Side effects uses
Tarlatamab-dlle injection is used to treat extensive stage small cell lung cancer (ES-SCLC) that has spread throughout the lung or to other parts of the body in patients who have received other cancer medicines (eg, platinum) that did not work well
|
|
|